Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Overt Hepatic Encephalopathy
Conditions
Keywords
neurophysiologica tests, diagnosis, minimal hepatic encephalopathy, overt hepatic encephalopathy, liver cirrhosis, acute on chronic liver failure, blood biomarkers
Brief summary
The study analyzes the diagnostic efficacy of neurophysiological tests and blood biomarkers on MHE, predicts risk factors on the development of OHE and investigate the mortality of MHE in patients with cirrhosis and acute on chronic liver failure.
Detailed description
Hepatic encephalopathy (HE) is a common complication and one of the most serious manifestations of cirrhosis and acute on chronic liver failure, not only increasing the risks of death, but also seriously affecting the lives of the patients and their caregivers. Minimal hepatic encephalopathy (MHE), the earliest stage of HE, despite its undiscernible clinical evidence, it is related with abnormalities of patients' daily cognition, emotion, muscular strength, driving ability, quality of life and socioeconomic status At present. However, MHE is not easy to diagnose in daily clinical work because of time-consuming psychometric tests, especially the inconvenience of application in weak inpatients. This study aims to analyze the diagnostic efficacy of neurophysiological tests and blood biomarkers on MHE, predict risk factors on the development of OHE and investigate the mortality of MHE in patients with cirrhosis and acute on chronic liver failure.
Interventions
DIAGNOSTIC_TESTneurophysiological tests, blood biomarkers.
Let the patients do neuropsychological tests and detect blood biomarkers.
Sponsors
Qin Ning
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* \>18 years old * cirrhosis * acute on chronic liver failure
Exclusion criteria
(1) status of OHE; (2) accompanying nervous system diseases, such as dementia or stroke; (3) a history of recent head trauma or surgery, and (4) organic lesions in the brain, such as haemorrhages or infarction; (5) inability to finish the psychometric hepatic encephalopathy score (PHES), such as unable to observe patterns or words clearly on paper, and (6) a recent transjugular intrahepatic portosystemic shunt (TIPS) or abdominal imaging demonstrated portosystemic shunts, and (7) high alcohol consumption (\> 30 g/day in men or 20 g/day in women) or psychoactive medication consumption in the past four weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression of 2-4 HE | 30 days | Incidence of HE progression (2/3/4 HE) |
| mortality in short, median and long term | 30 and 90 days, 1, 2, 3 years | mortality in 30 days, 90 days, 1 year, 2 years, 3 years |
Countries
China
Outcome results
None listed